Related Experiment Video
Updated: Apr 19, 2026
11:19
Robotic Myotomy and Partial Fundoplication for Achalasia
Published on: August 11, 2023
2.2K
AGIBOT AM1000 versus da Vinci Xi systems for robot-assisted partial nephrectomy: a retrospective propensity
Shu Gao1, Jiyuan Sun1, Yan Zhu1
1Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, China.
Summary
Robot-assisted partial nephrectomy (RAPN) using the AGIBOT AM1000 system demonstrated comparable short-term outcomes to the da Vinci Xi platform. This study confirms the AGIBOT AM1000
Area of Science:
- Urology
- Robotic Surgery
- Nephrology
Background:
- Robot-assisted partial nephrectomy (RAPN) is a standard treatment for clinical T1 renal tumors.
- The comparative effectiveness of the AGIBOT AM1000 system versus the established da Vinci Xi platform for RAPN is not well-defined.
Purpose of the Study:
- To evaluate the noninferiority of the AGIBOT AM1000 system compared to the da Vinci Xi platform in robot-assisted partial nephrectomy.
- To assess short-term perioperative outcomes and feasibility of the AGIBOT AM1000 system for RAPN.
Main Methods:
- A single-center, retrospective, propensity score-matched noninferiority study.
- Included adult patients undergoing RAPN between December 2023 and December 2025.
- Primary endpoint: operative success rate (completion without conversion); noninferiority margin set at -10%.
Main Results:
- Propensity score-matching yielded 49 patients in both the AGIBOT and da Vinci groups.
- 100% operative success rate in both groups, meeting the noninferiority criterion (risk difference 0.0%).
- AGIBOT AM1000 showed significantly lower estimated blood loss and hemoglobin decrease, with comparable operation time, warm ischemic time, and complication rates.
Conclusions:
- The AGIBOT AM1000 system is a feasible platform for robot-assisted partial nephrectomy.
- Short-term perioperative outcomes of RAPN using AGIBOT AM1000 are comparable to the da Vinci Xi system.
